Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07281677
PHASE4

Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years

Sponsor: Zhejiang Provincial Center for Disease Control and Prevention

View on ClinicalTrials.gov

Summary

This study aims to assess the immunogenicity and safety of a sequential 2vhpv to 9vhpv immunization schedule in girls aged 9-14 years

Official title: Immunogenicity and Safety of Sequential Bivalent and 9-Valent Human Papillomavirus Vaccine Immunization in Girls Aged 9-14 Years

Key Details

Gender

FEMALE

Age Range

9 Years - 14 Years

Study Type

INTERVENTIONAL

Enrollment

400

Start Date

2025-12-20

Completion Date

2029-11-13

Last Updated

2025-12-15

Healthy Volunteers

Yes

Conditions

Interventions

BIOLOGICAL

bivalent HPV vaccine

Bivalent HPV vaccine produced by Shanghai Zerun Biotechnology Co.,Ltd. or Wantai BioPharm.

BIOLOGICAL

9-valent HPV vaccine

9-valent HPV vaccine is produced by Wantai BioPharm or Merck Sharp \& Dohme LLC.

Locations (1)

Jinyun center for Disease Control and Prevention

Lishui, Zhejiang, China